Home/Pipeline/OBI-902

OBI-902

Solid Tumors (TROP2‑expressing)

Phase 1/2Active

Key Facts

Indication
Solid Tumors (TROP2‑expressing)
Phase
Phase 1/2
Status
Active
Company

About OBI Pharma

Taiwan‑based ADC specialist OBI Pharma advances glycan‑engineered antibody‑drug conjugates for oncology.

View full company profile

Therapeutic Areas